Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495466 | 1.00 | KMT2A (0.41) | KMT2ANAMPTROCK2CYP19A1CXCR4 | |
| SCHEMBL4497985 | 0.91 | ROCK2 (0.40) | NAMPTROCK2 | |
| SCHEMBL4497979 | 0.91 | ROCK2 (0.40) | NAMPTROCK2 | |
| SCHEMBL4477014 | 0.90 | ROCK2 (0.40) | NAMPTROCK2 | |
| SCHEMBL4477010 | 0.90 | ROCK2 (0.40) | NAMPTROCK2 | |
| SCHEMBL226962 | 0.87 | ROCK2 (0.48) | NAMPTROCK2 | |
| SCHEMBL226963 | 0.87 | ROCK2 (0.48) | NAMPTROCK2 | |
| SCHEMBL4504092 | 0.86 | BACE1 (0.43) | NAMPTROCK2 | |
| SCHEMBL4504089 | 0.86 | BACE1 (0.43) | NAMPTROCK2 | |
| SCHEMBL4500818 | 0.86 | OPRK1 (0.39) | KMT2ANAMPTROCK2LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | KMT2A 3530/4885NAMPT 3483/4885ROCK2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.